Prostate cancer and impotence fresh information.

By The Canadian Press

TORONTO - Health Canada is warning consumers not to use two supplements sold as natural erectile dysfunction products because they contain a prescription medication.

The products, marketed under the brand names Axcil and Desirin, contain sildenafil.

Health Canada says Axcil and Desirin aren’t licensed for sale in Canada and haven’t been found on store shelves here, but may have been brought back to the country by travellers to the United States.

Sildenafil, which is contained in Viagra and some other erectile dysfunction medications, should only be taken under the guidance of a health professional.

When used by people with heart disease, sildenafil can lead to serious cardiovascular side-effects such as sudden cardiac death, heart attack, stroke, hypertension, chest pain and abnormal heartbeat.

Sildenafil can also be associated with temporary vision loss, seizure, prolonged erection, headache, flushing, nasal congestion and abdominal pain.

It should not be used by individuals taking any type of nitrate drug such as nitroglycerine; the could lead to low blood pressure.

LIKE IT?LET OTHERS KNOW

Thanks for participating!

Be the first to recommend - Sign in now

See what other people are - Popular Stories

CME Outfitters announces an upcoming live and interactive CME/CE symposium titled “Recognition and Management of Erectile Dysfunction in Patients with Comorbidities: A Case-Based Approach.” Scheduled for Saturday, December 8, 2007, from 3:45-5:15 p.m. CT, the symposium will provide an update on the relationship between ED, vascular disease, related comorbidities, and effective treatment. The symposium is offered as part of the Sexual Medicine Society of North America (SMS) 2007 Fall Meeting.

Rockville, MD (PRWEB) November 19, 2007 — CME Outfitters, LLC, an independent accredited provider of multidisciplinary medical education programming and related healthcare services, is pleased to announce an upcoming live and interactive CME/CE symposium titled “Recognition and Management of Erectile Dysfunction in Patients with Comorbidities: A Case-Based Approach.”

Scheduled for Saturday, December 8, 2007, from 3:45-5:15 p.m. CT, the symposium will provide an update on the relationship between ED, vascular disease, related comorbidities, and effective treatment.

The symposium is offered as part of the Sexual Medicine Society of North America (SMS) 2007 Fall Meeting, which will be held from December 6-9, 2007, at the Westin Chicago River North in Chicago, Illinois.

To attend this symposium, it is necessary to register in advance for the SMS Fall Meeting. To register online, visit https://www.smsna.org/meetings/832/register.aspx

There is no additional fee to participate or receive CE credit for this symposium; however, advance registration is requested. Two forms of registration are accepted:
Online: Visit the activity details page at http://www.cmeoutfitters.com/cmea.asp?ID=273 and click the Register icon.
Phone: Call 877.CME.PROS (877.263.7767).

Statement of Need:
Erectile dysfunction (ED) is a common problem in countries, with a prevalence of approximately 50% in men aged 40 to 70 years. A strong relationship has been demonstrated between vascular disease, diabetes mellitus, hyperlipidemia, and ED.

The Expert Panel on “Erectile Dysfunction as a Risk Factor for Coronary Heart Disease: Implications for Prevention” states that, “ED is an early marker of a systemic process. … Asymptomatic men presenting with ED provide an important opportunity to screen for cardiovascular risk factors and detect silent CHD.”

In a study of more than 7,600 men with hypertension, 77% of a subgroup who also had diabetes reported ED. Eighty percent of those men classified their ED symptoms as bothersome, yet less than 40% were receiving treatment. A majority of physicians report not feeling confident in managing ED in patients with vascular comorbidities. This represents a serious gap in treatment for patients with these disorders.

In this interactive, case-based symposium, the experts will examine the barriers to recognition, diagnosis, and treatment of ED and comorbid vascular disease and explore strategies for achieving treatment goals and improving patient outcomes.

Faculty:
Arthur L. Burnett, II, MD
Professor of Urology
Director, Basic Science Laboratory in Neuro-urology
Director, Male Consultation Clinic
Johns Hopkins University School of Medicine
Baltimore, MD

Serge Carrier, MD, FRCS(C)
Assistant Professor of Surgery
Urology Program Director
Division of Urology
McGill University
Montreal, Quebec

Agenda:
3:15-3:45 p.m. - Registration
3:45-4:15 p.m. - “Examining the Impact of Comorbidities on Erectile Dysfunction” - Arthur L. Burnett, II, MD
4:15-4:45 p.m. - “Treatment Options for Managing Patients with Erectile Dysfunction and Comorbidities” - Serge Carrier, MD, FRCS(C)
4:45-5:15 p.m. - Panel Discussion/Q&A Session

Learning Objectives:
At the end of this CE activity, participants should be able to:
- Discuss the relationship between erectile dysfunction (ED) and vascular disease, diabetes mellitus, and hyperlipidemia.
- Recognize opportunities for early identification of comorbidities associated with ED.
- Compare and contrast the different therapies available for patients with ED and comorbidities.

Target Audience:
Physicians and other healthcare professionals interested in erectile dysfunction and vascular disease.

Commercial Support:
CME Outfitters gratefully acknowledges an educational grant from Schering-Plough Corporation and in support of this CME activity.

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

About CME Outfitters:
CME Outfitters develops and distributes live, recorded, print, and web-based educational activities to thousands of clinicians each year and offers expert accreditation services for non-accredited organizations. For a complete catalog of certified activities, please visit http://www.cmeoutfitters.com, http://www.neuroscienceCME.com, or call 877.CME.PROS (877.263.7767).

To view all recent CME Outfitters press releases, visit http://www.cmeoutfitters.com and click on “News” or visit http://www.prweb.com and search for “CME Outfitters.”

About the Sexual Medicine Society:
Established in 1994 as an independent organization of health care professionals concerned with the science of human sexual function and dysfunction, the Sexual Medicine Society of North America, Inc. (SMS) strives to:
- Promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of the anatomy, physiology, pathology, diagnosis, and treatment of human sexual function and dysfunction.
- Provide a forum for the free exchange and discussion of new ideas, thoughts, and concepts in this field.
The SMS seeks to identify existing and emerging issues in the field of human sexual function and dysfunction, provide accurate and credible information to medical professionals, develop standards and guidelines for impotence research and practice, and produce educational program that bring leading-edge concepts of research, clinical practice, ethics, and politics to health care professionals interested in impotence and related matters.

Contact: Jessica Primanzon
CME Outfitters, LLC
240.243.1308 direct
240.243.1033 fax

# # #

CME Outfitters, LLC
Jessica Primanzon
240.243.1308
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/U2luZy1Qcm9mLVBpZ2ctSG9yci1UaGlyLVplcm8=

Generic Viagra (www.genericviagra.me.uk) prove that recent studies show that the erectile drug Viagra could be link to be the cure for jetlag.

London, England (PRWEB) December 2, 2007 — It is usually not known that there is a certain link between Jetlag and Viagra. A recent study has shown that not only does Viagra treat erectile dysfunction but it can actually also neutralize the effects of jetlag. Viagra has been observed to restore normal bodily clock functions which have been shifted by six hours.

Viagra was first developed by Pfizer for aid in treatment of angina and high blood pressure by the enzyme that causes the reduction of cGMP, a natural compound, cGMP plays a very important in the function of penile erection.

In relation to jetlag, cGMP acts in a region of the brain whose role is to regulate the circadian cycle. The circadian cycle is the body's internal clock that the waning and the waxing of hormones and also controls the urge to sleep and wake.

In a laboratory test, hamsters were injected with Viagra and subjected to bright lights for 6 hours ahead of the regular time. They were observed by a team of researchers from the Universidad Nacional de Quilmes. They found that the injected hamsters have improved in coping with the time difference by 25 to 50 percent as those compared to the hamsters that were not administered with Viagra. The testing gave out a positive result in the light to dark cycle which is the equivalent of traveling from west to east.

Further test is needed to really identify the of Viagra as an effective treatment to counter the ill feeling of traveler's jetlag. If this can be validated, then the blue pill can cross the barrier of time and human dysfunction.

About Generic Viagra
Generic Viagra have been one of the UK's leading suppliers for male impotence drugs since April 2007, forever expanding product range and bringing a bright light to erectile dysfunction. For more information, please visit http://www.genericviagra.me.uk , or contact Terry Bytheway at ( 44) 01299824653.

###

Terry Bytheway
+44 01214585844
E-mail Information

Trackback URL: http://prweb.com/pingpr.php/UHJvZi1Ib3JyLVByb2YtSG9yci18=

- The drugmaker Eli Lilly and Co. said Tuesday that Sidney Taurel will retire as chief executive on March 31 after nearly a decade in the post, and plans to step down as chairman at the end of 2008.

President and Chief Operating Officer John C. Lechleiter was named to take over as CEO on April 1.

Taurel, 58, has been Lilly’s CEO since July 1998 and chairman since January 1999.

The retirement announcement didn’t surprise Lehman Brothers analyst Tony Butler.

“He’s still young for retirement age, but … he has been CEO since ‘98,” Butler said, adding that it was apparent Lechleiter would take over when the company promoted him to president and COO in 2005.

Lilly’s shares rose 72 cents, or 1.4 percent, to $53.91 in morning trading Tuesday.

Lechleiter, 54, joined Lilly in 1979. He will continue as president besides his new role of CEO. He studied organic chemistry at Harvard, where he received a master’s degree and a doctorate.

Butler said Lechleiter’s chemistry background will reinforce the emphasis Lilly places on research and development to find new drug molecules.

Miller Tabak and Co. analyst Les Funtleyder said the company didn’t “telegraph” that the retirement was coming, but he also wasn’t surprised by the news.

The new CEO comes “highly regarded” by Wall Street, according to Funtleyder. But the analyst added that Lechleiter’s reputation only helps so much.

“Ultimately, a lot of Lilly’s fate lies in the hands of its scientists to bring out new drugs,” he said. “Lechleiter could put together a good strategy, but they still need to bolster that pipeline somehow.”

He said he wants to hear more about the new CEO’s plans.

“They have the same problems as other pharma companies, they need to develop new drugs, and they need to defend their existing products,” he said. “I mean its been difficult for many.”

Taurel joined Lilly in 1971 as a marketing associate. He then served as the general manager of a Lilly affiliate in Brazil and as the London-based vice president of Lilly’s European operations.

He later became an executive vice president of the company and president of the division. In 1996, he was promoted to president and chief operating officer.

“I am grateful to have spent nearly 37 years with this great company, and deeply honored to have had the opportunity to lead it for the last 10,” Taurel said in a statement. “John has been preparing for his new role as my successor for several years, and 2008 is the right time for him to assume his place as the leader of the company.”

Taurel steered Lilly through the loss of patent protection for its then top-selling drug, Prozac, in 2000. The drug once topped $2 billion in annual sales but brought in only $285 million last year.

Before this, the pharmaceutical industry had never seen managed care’s impact on a brand-name drug after it lost patent protection, Butler said.

“No management in the pharmaceutical industry would have been prepared for that, but Lilly somehow was,” Butler said. “While they had a year down in revenue, they bounced back very quickly and were able to launch quite a few new drugs.”

Earlier this month, Lilly issued a 2008 profit forecast above analyst expectations, predicting strong sales of antidepressant Cymbalta, erectile treatment Cialis and diabetes drug Byetta. Lilly has said it plans to launch six new drugs or new formulations of existing drugs by 2011.

It also aims to have 10 drug compounds in late-stage clinical testing by 2011 and wants to launch two new compounds per year beginning in 2011, increasing to three per year by 2014. The forecast has been a boon to Lilly’s shares, as most major pharmaceutical stocks have fallen as investors become apprehensive about expiring patents on blockbuster drugs which have driven profits for years.

Here are some of the latest health and medical news developments,
compiled by editors of HealthDay:

Health Experts Warn of Loss of Momentum in
Fight Against Smoking

Noting that U.S. smoking rates are stagnant after nearly a decade of
decline, a coalition of public health organizations warned Wednesday that
the nation's progress in reducing smoking is at risk unless states
significantly increase funding for programs to prevent children from
smoking and help smokers quit.

The warning, contained in an annual report, assesses whether states are
keeping their promise to use proceeds from the 1998 state tobacco
settlement to fight tobacco use. This year, the report found that states
have increased funding for tobacco prevention and cessation programs by 20
percent — to $717.2 million, the highest level in six years.

But, most states still fail to fund these programs at minimum levels
recommended by the U.S. Centers for Disease Control and Prevention, and
the states combined are providing less than half of what the CDC has
recommended, the report said.

The report, “A Broken Promise to Our Children: The 1998 State Tobacco
Settlement Nine Years Later,” was released by the Campaign for
Kids, the American Heart Association, the American Lung
Association and the American Cancer Society Cancer Action Network.

Among the report's findings:

• Only three states — Maine, Delaware and Colorado — currently fund
  tobacco prevention programs at CDC minimum levels.
• Only 17 other states fund tobacco prevention programs at even half the
  CDC's minimum amount.
• Thirty states and the District of Columbia are spending less than half
  the CDC minimum, while Connecticut has no funding for tobacco
  prevention this year.
• Total state funding for tobacco prevention amounts to less than 3
  percent of the record $24.9 billion the states will collect this year from
  the tobacco settlement and tobacco taxes. Just 6.4 percent of this
  tobacco revenue would fund prevention programs in every state at CDC
  minimum levels.
• The states' funding of tobacco prevention pales compared to the $13.4
  billion a year spent on tobacco marketing and the nearly $100 billion
  spent each year on health-care bills due to tobacco use.

The report comes as recent surveys have found that the nation's
progress in reducing smoking has stalled among both children and adults.
The CDC recently reported that 20.8 percent of adults smoked in 2006,
about the same as the 20.9 percent in 2004 and 2005. This followed a
steady decline between 1997 and 2004. High school smoking rates have
similarly stalled after declining from a high of 36.4 percent in 1997, and
23 percent of high school students still smoke, according to the most
recent CDC data cited by the report.

The CDC has attributed this stall to several factors, including cuts in
tobacco prevention funding, increases in tobacco marketing and stagnant
cigarette prices due to industry discounting.

“It is to stand still in the fight against the number one
preventable cause of death in our country,” said William V. Corr,
executive director of the Campaign for Tobacco-Free Kids. “As the
Institute of Medicine and the President's Cancer Panel found, we know what
works to reduce smoking, save lives and save money by reducing
tobacco-related health care costs. What's needed is the political
leadership to fund and implement these measures as aggressively as the
tobacco companies continue to market their deadly and addictive products.”

Tobacco use is the nation's leading preventable cause of death, killing
more than 400,000 people and costing nearly $100 billion in health-care
bills each year, the report said.

—–

U.S. Cholesterol Average Drops to New Low

For the first time since it began in 1960, a national survey has found
that the average total cholesterol level among American adults is in the
ideal range. The average level in 2005-2006 was 199, according to the
survey of about 4,500 people 20 and older. A level of 200 or less is
desirable.

The National Center for Health Statistics conducts the blood test
survey in two-year intervals. The average total cholesterol level was 204
in 1999-2000 and 222 in 1960, the Associated Press reported.

The new survey also found that the percentage of adults with high
cholesterol (240 or higher) was 16 percent, compared to 20 percent in the
early 1990s. Among survey respondents, 65 percent of men and 75 percent of
women had been screened for high cholesterol in the previous five
years.

A primary reason for the positive news may be rising use of
cholesterol-lowering drugs in people 60 and older, said report author
Susan Schober, a senior epidemiologist at the National Center for Health
Statistics, the AP reported.

“These age groups are the ones most likely to be treated with
medication,” she said.

—–

Annual U.S. Hospital Bill May Hit $1 Trillion
in 2008: Report

In 2005, U.S. hospitals charged a combined $873 billion for patient
treatment, nearly 90 percent more than the $462 billion cumulative
hospital bill in 1997, according to the latest News and Numbers
from the federal Agency for Healthcare Research and Quality.

Over the past several years, the average annual rate of increase in the
national hospital bill was 4.5 percent. At that rate, the annual tally may
hit $1 trillion by 2008, the report said.

Medicare paid the majority of the 2005 national hospital bill ($411
billion), followed by private insurers ($272 billion) and Medicaid ($124
billion). Uninsured patients accounted for $38 billion in charges. The
remaining $28 billion was paid for by other insurers, including Workers'
, TRICARE, Title V, and other government programs.

Five conditions accounted for a considerable chunk of the national
hospital bill: coronary artery disease ($46 billion); pregnancy and
childbirth ($44 billion); newborn infant care ($35 billion); heart attack
($32 billion); and congestive heart failure ($30 billion).

—–

U.S. and China Sign Drug and Food Safety
Accords

After nearly seven months of negotiations, the United States and China
have signed a pact to strengthen regulation of drugs and medical devices
exported to the United States, The New York Times reported.

Under the accord, all Chinese companies that make certain drugs for
export to the United States will have to register with Chinese regulators.
Drugs covered under the pact include the cholesterol-lowering drug
atorvastatin (Lipitor), the erectile dysfunction drug sildenafil (Viagra),
and the antibiotic gentamicin sulfate.

However, the pact does little to regulate bulk pharmaceutical
ingredients made by thousands of unlicensed chemical companies in China.
Some of those ingredients are substandard and dangerous, the newspaper
said.

While this agreement doesn't address all areas of concern, American
officials said it's an important first step in helping the Chinese
government regulate unlicensed companies, the Times reported.

The United States and China also signed an agreement that places new
registration and inspection requirements on 10 food products exported by
Chinese companies. The specified products include some preserved foods,
pet foods and farm-raised fish, all of which have come under suspicion of
being tainted, The Times said.

—–

People With Asian Ancestry Should Be Tested
Before Taking : FDA

Drugs that contain the active ingredient carbamazepine will carry a
warning that patients with Asian ancestry should get a genetic blood test
before taking the drugs. The test will determine if they're at increased
risk for rare, but serious, skin reactions, the U.S. Food and Drug
Administration
said Wednesday.

Drugs that contain carbamazepine — sold under the brand names
Carbatrol, Equetro and Tegretol — are used to treat epilepsy, bipolar
disorder and neuropathic pain.

The risk of skin reactions — which can include lesions, blisters,
fever and itching — is about 1 to 6 people per 10,000 among new users of
such drugs in countries with mainly white populations. However, the risk
is estimated to be about 10 times higher in some Asian countries.

It's estimated that about 5 percent of patients being considered for
treatment with affected drugs are of Asian ancestry and would need to have
this test, which looks for an inherited variant of an immune system gene
found almost exclusively in people with Asian ancestry, the FDA said.

Patients who test positive shouldn't be treated with carbamazepine
unless the benefit clearly outweighs the increased risk of serious skin
reactions, the agency said.

—–

Excess Weight Reduces Women's Fertility:
Study

The more overweight a woman becomes, the less fertile she becomes,
according to results of a Dutch study published in the journal Human
Reproduction.

Researchers evaluated 3,000 women with fertility problems and found
that every point increase in body mass index (BMI) among women with a BMI
between 30 and 35 resulted in a 4 percent decrease in conception rates,
compared to women with a BMI between 21 and 29, BBC News
reported.

People with a BMI above 25 are considered overweight, while those with
a BMI over 30 are defined as obese.

The study also found that severely obese women (a BMI greater than 35)
were between 26 percent and 49 percent less likely to get pregnant than
those with a BMI between 21 and 29, BBC News reported.

“Given the increased prevalence of obesity, this is a worrying
finding,” said study leader Dr. Jan Willem van der Steeg. “We think women
should be informed about their lower pregnancy chances due to their
overweight.”

The researchers suggested that losing weight may increase the
likelihood of conception without the need for fertility treatment, BBC
News reported.

—–

Death Toll Reaches 30 in Uganda Ebola
Outbreak

The death toll from an Ebola outbreak in Uganda is now 30 out of 116
people known to have been infected with the deadly virus, Agence
France-Presse reported.

Health officials are still registering new infections in Bundibugyo
district, the epicenter of the outbreak and home to 250,000 people.
Hundreds of medical workers and villagers who have had physical contact
with infected patients are under observation, Ugandan authorities
said.

Experts from the U.S. Centers for Disease Control and Prevention are
continuing their testing for the virus, which has been identified as a new
strain of Ebola, AFP reported. The outbreak began in September but
was only identified as Ebola in late November.

Ebola is a blood-borne disease that's spread through contact with
bodily fluids.

If a patient experiences discomfort because of his failures it may these feelings may influence erection in their turn and make the problem worse.

The first thing partners shall do is to admit the fact that the problem exists and discuss this issue openly between them.

Self Esteem
Sexual strength plays an important part in men vision of the world and their position in it. So erectile dysfunction ruins not only sexual life, but also man’s his perceive of life. Patient begins to doubt about himself and try to minimize contact with partner that raises additional negative emotions. Though the reason of all this may be treated in most part of cases.

Men with ED try to reduce communication and distance from their partners and close and sometimes have wrong vision of their role in it.

ED may affect any aspect of life or all of them: love, work, sports, friendship and etc. Frustration changes the character and impacts performance. It becomes a problem that shall be resolved as soon as possible before it ruins the whole life. A man with ED shall first of all discuss his disorder with his partner and turn to physician and agree with his a treatment that may help him to cure ED and overcome its .

Partners
It is hard to speak about erectile dysfunction both with doctor and with partner. Often men prefer to keep silence and avoid contacts and frank communication with those who love them that adds more problems to relationships.

In their turn partners prefer to keep silence and do not start on this topic not to hurt the man with ED. They may think that their partner are not interested in them and feel guilty for his ED.

Usually ED is caused by physical reasons and it can be treated and healed in majority of cases. But anxiety, mistrust, isolation and frustration have a strong impact on erection and make it worse and this in its turn leads to more negative feelings for both.

It is very important to understand that ED is a physical condition that is rarely hopeless. It may be cured if a couple takes a decision to solve this problem with mutual support and and turn to physician.

Diagnosis
As the result of medical examination neurological, vascular, or hormonal disease, or Peyronie's disease can be found. Usually thorough examination of health conditions like history of illness, smoking, drug use, and hypertension is needed as well as laboratory tests.

Blood Tests and Urinalysis
Laboratory of hormone levels, cholesterol, blood sugar, liver and kidney function, and thyroid function may show what influences erection. E.g. it may turn to be that there is excess prolactin (hyperprolactinemea) that causes decrease of libido. The levels of sex hormones are measured. In case these levels are not normal the patient should go to an endocrinologist.

CBC-Complete blood count (CBC) of red cells and white cells is done to verify anemia. If the number of red cells is below normal it may cause oxygen starvation and general fatigue. Arteriosclerosis may prevent blood from flowing to penis. Its presence may be seen from the level of blood lipids (fats) such as cholesterol and .

Liver and kidney function tests - the consequence of liver and kidney disease may be hormonal imbalances. The indicators of kidney efficiency are enzyme and serum creatinine levels.

Thyroid function tests - A deficit of thyroid hormones that regulates metabolism and the production of sex hormones may also lead not impotence.

Urinalysis -Analysis of urine for protein (albumin), sugar (glucose), and hormone () that helps to verify presence of diabetes mellitus, kidney dysfunction, and testosterone deficiency.

Erectile Function Tests
Examination of the blood vessels, nerves, muscles, and other tissues that are located in the penis and pelvic region.

Duplex ultrasound -This test is applied to see the parameter of blood flow, venous leak, signs of , and scarring or of erectile tissue. Injection of prostaglandin produced in the body stimulates erection. The ultrasoud analysis shows vascular dilation and penile blood pressure (a special cuff may be applied to measure it). The results a liable to comparison with those of flaccid penis.

Prostate examination - This test is used to see if the prostate is enlarged that may be revealed in digital rectal examination (DRE). If this happens, the blood supply of penis changes.

Penile nerve function - Sufficient nerve sensation is tested by bulbocavernosus reflex test. The glans (head) of the penis is squeezed while this process. If sensation is normal anus shall. The latency between squeeze and contraction is measured by examining the anal sphincter. Also a gloved finger inserted in the anus may be used. When there is nerve damage caused by diabetes or nerve disease other tests shall be applied.

Nocturnal penile tumescence (NPT) - Normal man experiences 5-6 erection while he is sleeping, they are most frequent at the phase rapid eye movement (REM). The frequency of them is 90 minutes and usually they last 30 minutes. If there is no it means that there are problems with nerves or blood. Two methods of measuring penis conditions at nocturnal erections are known. These are: snap gauge and strain gauge.

For snap gauge three plastic bands of difference strength are wrapped around the penis. The break of them indicates erectile. For strain gauge special elastic bands are put on the base and tip of the penis. When the penis erects they stretch, so circumference is measured.

Penile biothesiometry - Sensitivity and nerve function in the glands and shaft of the penis is tested involving electromagnetic vibration. Nerve damage can be revealed in the pelvic area this way.

Vasoactive injection - There are solutions that dilate blood vessels in erectile tissue that stimulate erection. Erection caused this way shall last 20 minutes. These solutions are injected to penis in this test to measure penile and x-rays snap of blood vessels involving a contrast agent may be taken.